New drug targets cancer spread in first human trial

NCT ID NCT04222413

Recruiting now Disease control Sponsor: National Cancer Institute (NCI) Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Aug 12, 2026 · Updated 10 times

Summary

This early-phase trial tests a new drug called metarrestin in people with advanced solid tumors that have spread (metastasized). The goal is to find a safe dose and see if it can shrink tumors. The study includes adults with pancreatic, breast, or other solid tumors, and children aged 12-17 with certain solid tumors. Participants take metarrestin by mouth and are closely monitored.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Metarrestin (ML-246)
What this could lead to: If it works, this could point toward a new treatment that slows or shrinks metastatic solid tumors, potentially improving outcomes for patients with advanced cancer.
What could go wrong: This is a very early Phase 1 trial focused on safety and dosing, so it is unknown if metarrestin will effectively shrink tumors. Side effects may occur, and the drug may not work for all cancer types studied.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ADVANCED BREAST CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

breast cancer childhood neoplasm colorectal cancer colorectal neoplasm malignant pancreatic neoplasm malignant peripheral nerve sheath tumor metastatic malignant neoplasm metastatic neoplasm neurofibrosarcoma pancreatic neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ADVANCED BREAST CANCER ADVANCED SOLID TUMORS COLORECTAL NEOPLASMS MALIGNANT PERIPHERAL NERVE SHEATH TUMOR METASTATIC PANCREATIC CANCER PEDIATRIC SOLID TUMOR

Contacts and locations

Locations

National Institutes of Health Clinical Center
RECRUITING

Bethesda, Maryland, 20892, United States
University of Kansas
RECRUITING

Fairway, Kansas, 66205, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.